Please login to the form below

Not currently logged in
Email:
Password:

ANAVEX2-73

This page shows the latest ANAVEX2-73 news and features for those working in and with pharma, biotech and healthcare.

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

Anavex’s CNS drug slows progression of motor and non-motor symptoms in Parkinson’s disease

This is now the second independent placebo-controlled clinical ANAVEX2-73 phase 2 study to confirm the predictive biomarker of response established with SIGMAR1 mRNA expression. ... This data further strengthens the foundation of ANAVEX2-73 as a

Latest news

More from news
Approximately 1 fully matching, plus 0 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Top 10 ways to leverage the Impetus InSite Platform® to (virtually) launch your brand
The Impetus InSite Platform® can be used to facilitate virtual and hybrid engagement at all stages of the product lifecycle. Here, we share 10 of the most popular ways to...
Employee wellbeing in creative agencies: three tips to get you started
Paul Hutchings, founder of fox&cat, and new friend, Welfy, a workplace wellbeing training firm, discuss the importance of collaboration...
Managing unhelpful pressure in your creative agency: the human approach
Paul Hutchings, founder of fox&cat, answers the questions: what does it mean to be human in 2021? Are we putting ourselves under too much pressure?...